Alle Studien
RekrutierungPHASE3INTERVENTIONELL

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

This study is looking into a new medicine called marstacimab for young people aged 1 to 17 who have haemophilia A or B. Haemophilia is a condition where blood doesn't clot properly, leading to bleeding. The main goal is to find out if marstacimab is safe and helps prevent these bleeding episodes. Participants will receive marstacimab as a weekly injection under the skin, often at home, for 12 months. Researchers will compare their bleeding experienced during the study with their past health records to see if the medicine makes a difference. The study involves regular check-ups and phone calls over about 14 months.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE3
Sponsor
Pfizer
Einschreibeziel
100
Starten
09 Dec 2022
Geschätzte Fertigstellung
10 Sep 2028

Worum geht es in dieser Studie?

Haemophilia A and B are conditions where your blood doesn't clot as it should, which can lead to bleeding that is hard to stop. This often means facing painful and sometimes serious bleeding episodes. Doctors and researchers are always looking for new treatments that can make life easier and safer for people with haemophilia, especially children and teenagers.

This study is focusing on a new medicine called marstacimab. We want to understand if this medicine is safe and if it can help prevent bleeding in young people (aged 1 to 17 years old) who have haemophilia A or haemophilia B. Participants will receive marstacimab as a weekly injection under the skin, similar to a regular shot you might get at the doctor's office, but you might be able to do this at home after the first dose.

The study will follow participants for about 14 months in total. During this time, the research team will keep a close eye on their health and any bleeding episodes. They will compare these experiences to how the participants were doing before the study, to see if marstacimab helps to reduce the frequency and severity of bleeding events.

Wichtige Erkenntnisse

  • New medicine (marstacimab) for haemophilia A or B.
  • For boys and young men aged 1 to 17.
  • Aims to reduce bleeding episodes.
  • Weekly injection, potentially at home.
  • Study lasts about 14 months with clinic visits and calls.
  • Focuses on safety and effectiveness compared to past health.

Wer könnte berechtigt sein?

This study is open to boys and young men aged between 1 and 17 years old. They need to have a confirmed diagnosis of severe haemophilia A or moderate to severe haemophilia B. It's important that they have good health records from the past year that show their previous treatments and any bleeding episodes.

For those without 'inhibitors' (substances that can make haemophilia treatment harder), they must have been on a stable, regular preventative treatment for at least a year. If they do have inhibitors, they need to have been on a specific type of treatment for bleeding for at least a year before joining the study.

There are also weight requirements for different age groups: teenagers (12-17) must weigh at least 25 kg, and children (6-11) must weigh at least 19 kg. The minimum weight for the youngest group (1-5) will be confirmed later.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Are you a male between 1 and 17 years old?
  2. Do you have severe haemophilia A or moderate to severe haemophilia B?
  3. Do you have health records for the past year showing your treatments and bleeding?
  4. If you don't have 'inhibitors', have you been on a stable, regular preventative treatment for at least a year?
  5. If you have 'inhibitors', have you been on a specific bleeding treatment for at least a year?
  6. Do you meet the weight requirements for your age group (e.g., 25 kg for 12-17 year olds)?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part, the study will last about 14 months. This includes an initial screening period of about a month, followed by 12 months when you’ll be receiving the study medicine, and then a month of follow-up. You will receive the study medicine, marstacimab, once a week as an injection just under the skin. The first dose will be given by the study staff, but after that, you might be able to give the weekly injections at home if you prefer and are able to. Over the 14 months, you will need to visit the study clinic at least 10 times. For some of these visits, if allowed, you might be able to have them at home instead. There will also be 6 phone calls spread out every couple of months to check in on you.

Potenzielle Risiken und Vorteile

Taking part in this study may offer potential benefits, such as receiving a new medicine that might help reduce bleeding episodes. However, as with any medicine, there could be side effects or risks that your study doctor will discuss with you. You will be closely monitored by the study team, and you are free to withdraw from the study at any time, for any reason, without it affecting your medical care.

Standorte (63)

  • Intermountain - Primary Children's Hospital
    Verifizierte Postleitzahl
    Salt Lake City, Vereinigte Staaten· Rekrutierung
  • Arbesu Hematología
    Verifizierte Postleitzahl
    Mendoza, Argentina· Rekrutierung
  • Murdoch Kinderforschungsinstitut
    Verifizierte Postleitzahl
    Parkville, Australien· Rekrutierung
  • Medizinische Universität Wien
    Verifizierte Postleitzahl
    Wien, Österreich· Rekrutierung
  • Centro Estadual de Hemoterapia e Hematologia Marcos Daniel Santos - HEMOES
    Unbestätigt
    Maruípe, Brazil· Aktiv, aber nicht rekrutierend
  • Stollery Children's Hospital
    Verifizierte Postleitzahl
    Edmonton, Kanada· Aktiv, aber nicht rekrutierend
  • Hamilton Health Sciences - McMaster University/McMaster Children's Hospital
    Verifizierte Postleitzahl
    Hamilton, Kanada· Aktiv, aber nicht rekrutierend
  • Beijing Children's hospital, Capital Medical University
    Verifizierte Postleitzahl
    Peking, China· Rekrutierung
  • Southern Medical University Nanfang Hospital
    Verifizierte Postleitzahl
    Guangzhou, China· Aktiv, aber nicht rekrutierend
  • The Affiliated Hospital of Guizhou Medical University
    Verifizierte Postleitzahl
    Guiyang, China· Aktiv, aber nicht rekrutierend
  • Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
    Verifizierte Postleitzahl
    Wuhan, China· Rekrutierung
  • Tongji Hospital of Tongji Medical College of HUST/Pediatric Hematology Department Pharmacy
    Verifizierte Postleitzahl
    Wuhan, China· Rekrutierung

Häufige Fragen

What is haemophilia?

Haemophilia is a condition where your blood doesn't clot properly, which can lead to longer or more frequent bleeding than usual.

What is marstacimab?

Marstacimab is the new medicine being tested in this study to see if it can help prevent bleeding in people with haemophilia.

Wie wird das Medikament verabreicht?

The medicine is given as an injection once a week, just under the skin. You might be able to do this at home after the first dose.

Wie lange dauert die Studie?

The study lasts for about 14 months in total, including screening, treatment, and follow-up.

Can girls or women join this study?

No, this study is only recruiting male participants.

Wie Sie mehr erfahren können

Pfizer CT.gov Call Center

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A Clinical Trial of Study Medicine (Marstacimab) in Pediatri… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.